Investigational drug · Phase 2
B7-H3 CAR-NK
Also called: EB-G3B7-NK dual-target CAR-NK cells, Dual-target GPC3, G3B7-NK, EB-G3B7-NK, EB-DTNB-NK, Dual-target GD2
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Relapsed Neuroblastoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "B7-H3 CAR-NK"
First trial start
2026
Mar 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B7-H3 CAR-NK", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Hepatocellular Carcinoma (HCC)
- Metastatic Liver Cancer
- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- High-Risk Neuroblastoma
- Ganglioneuroblastoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "B7-H3 CAR-NK" as an intervention, largest first.
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
- Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruiting
Beijing BiotechIndustry
NCT07480941 · 36 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 18, 2027
Drug: Dual-target CAR-NK cells; Cyclophosphamide and 1 more · For: Glioblastoma; High-grade Glioma; Malignant Glioma and 2 more
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07502287 · 36 participants (planned) · Start Mar 2, 2026 · Primary completion Mar 14, 2027
Drug: EB-DTNB-NK; Fludarabine and 1 more · For: Relapsed Neuroblastoma; Refractory Neuroblastoma; High-Risk Neuroblastoma and 1 more
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07551336 · 36 participants (planned) · Start Mar 2, 2026 · Primary completion Apr 14, 2027
Drug: Dual-target CAR-NK cells; Cyclophosphamide and 1 more · For: Malignant Glioma; High-Grade Gliomas; Glioblastoma and 2 more
Sites: Shenzhen, China
Beijing BiotechIndustry
NCT07500220 · 30 participants (planned) · Start Mar 2, 2026 · Primary completion Mar 14, 2027
Drug: EB-G3B7-NK dual-target CAR-NK cells; Fludarabine and 1 more · For: Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer
Sites: Shenzhen, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Hepatocellular Carcinoma (HCC)
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- AK105Phase 31 trial
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)
- WGI-0301Phase 22 trials
Zhejiang Haichang Biotech Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC), Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
- HA131Phase 21 trial
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.